Is OABI a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for OmniAb (OABI) rests on Clinical graduation across ~34 partner programs: The economics compound only as partner molecules move through phases, and 2026 delivered several jumps at once, including two programs advancing from Phase 1 to Phase 3 and four new clinical entrants through mid-year. The bear case rests on revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. Analysts covering it publish targets from $3.00 to $11.00 against a $3.38 price, so even the professionals disagree by 109% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

OmniAb was spun out of Ligand Pharmaceuticals in November 2022 and sells access to antibody discovery technology rather than drugs. Its platform centres on transgenic animals engineered to produce human-sequence antibodies (OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniClic) plus the xPloration high-throughput single-cell screening system and an ion channel screening group acquired with Icagen. Partners license the platforms, run their own discovery campaigns, and owe OmniAb payments at defined points: an upfront or annual access fee, service and instrument revenue, clinical and regulatory milestones, and a royalty on eventual product sales. As of Q2 2026 there were ~110 active partners, ~425 active programs, ~34 of those in clinical development or already approved, eight of the ten largest pharma companies among the partner base, and roughly 98% of programs carrying contracted future economics. Management has cited more than ~$3B of total contracted milestone potential at an average royalty near ~3.4%. The investment picture is unusually lumpy, because the revenue arrives when somebody else's molecule moves. Q2 2026 revenue was ~$13.4M against ~$3.9M a year earlier, almost entirely on license and milestone payments as programs such as Johnson & Johnson's ramantamig and Merck KGaA's precemtabart tocenteban jumped from Phase 1 into Phase 3. Net loss narrowed to ~$5.9M from ~$15.9M, and first-half operating cash burn fell to ~$2.2M from ~$21.0M. Set against that, trailing twelve-month revenue is only ~$38M on a ~$491M market value (roughly ~12.8x sales), the trailing net loss is ~$44M once amortisation of acquired intangibles is counted, and royalty revenue itself was just ~$0.3M in the quarter. On 17 August 2026 the company added a global collaboration and license agreement with Eli Lilly for an ion channel program and lifted year-end cash guidance to ~$49M to ~$53M from ~$37M to ~$41M, while leaving the 2026 revenue range at ~$32M to ~$36M.

The bull case: what would have to be true for $11.00

The most optimistic published target on OABI is $11.00, +225.4% from the $3.38 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Clinical graduation across ~34 partner programs

The economics compound only as partner molecules move through phases, and 2026 delivered several jumps at once, including two programs advancing from Phase 1 to Phase 3 and four new clinical entrants through mid-year. Each stage transition triggers a contracted milestone, and each approval converts a program from milestone payer into royalty payer. Because ~98% of active programs carry contracted future economics, the pipeline count is a reasonable proxy for the size of the eventual claim.

2. Milestone revenue reaching operating breakeven

Costs came down while revenue tripled: first-half R&D fell ~18% and G&A ~15% year over year, and operating cash use dropped to ~$2.2M for the half. Guidance frames 2026 GAAP operating expenses at ~$84M to ~$88M with cash expenses of ~$51M to ~$55M against ~$32M to ~$36M of revenue, so the gap is narrowing without new equity. No shares were issued under the ~$100M ATM in the first half, leaving ~$88.3M of that authorisation unused.

3. Business development that is paid up front

The August 2026 Lilly ion channel agreement carries an upfront payment plus eligibility for tiered royalties on global net sales, and it is what allowed the year-end cash outlook to rise by roughly ~$12M at the midpoint without touching the revenue range. Deals of this shape matter twice: they fund the platform today and add another royalty-bearing shot on goal later. Ion channel work also puts the Icagen assets back to use after a ~$2.9M intangible impairment in Q1 2026 tied to discontinued ion channel programs.

4. Royalties as the long-dated part of the story

Royalty revenue was ~$0.3M in Q2 2026 and ~$0.5M in the first half, so essentially none of the current valuation rests on realised royalties. The stated average rate of ~3.4% on partner net sales means the line only becomes material if several partner products reach commercial scale. Timing sits entirely with the partners, and a single large approval would change the revenue mix far more than any internal decision at OmniAb.

The bear case: what would have to be true for $3.00

The most pessimistic published target is $3.00, -11.2% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks OmniAb is worth if the risks below bite instead of the drivers above.

Revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. OmniAb controls none of the programs that pay it, so a partner deprioritising a molecule, a failed trial, or a slipped filing removes a milestone with no offsetting action available. The company remains unprofitable on a trailing basis (~$44M net loss) with a large non-cash amortisation charge on acquired intangibles, and Q1 2026 included a ~$2.9M impairment of a customer relationship intangible after ion channel programs were discontinued. Dilution mechanics are real even without an equity raise: ~145.4M shares outstanding sit alongside ~14.99M price-vesting earnout shares, ~18.6M warrants expiring 1 November 2027, and ~$88.3M of unused ATM capacity. Liquidity itself is not flagged as a concern (the 10-Q states cash is sufficient for at least twelve months and no going-concern warning is disclosed, no material pending legal proceedings are reported, and the shares remain listed on Nasdaq with no delisting determination), but the stock has traded between ~$1.30 and ~$3.64 over the past year and rose ~37% on the Q2 print, so the market value moves far more than the underlying contracts do.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding OABI already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on OABI

6 analysts cover OABI, with an average target of $7.33 (+116.9% against $3.38) and a split of 7 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the OABI forecast and price target page.

How is OABI valued? (as of August 2026)

Price

$3.3800

Market cap

$491.42M

Forward P/E

-11.36

Price / book

1.89

Beta

1.22

52-week range

$1.3000 to $3.6350

Snapshot for OABI as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$38M
Q2 2026 revenue: ~$13.4M, up from ~$3.9M a year earlier
2026 revenue guidance: ~$32M to ~$36M
Net loss: ~$5.9M in Q2 2026, ~$44M trailing twelve months
Cash and short-term investments: ~$52M at 30 June 2026; year-end guidance raised to ~$49M to ~$53M
Market value / price to sales: ~$491M, roughly ~12.8x TTM revenue

A ~12.8x multiple on ~$38M of trailing revenue is a platform multiple, not a biotech-pipeline multiple, and it reflects contracted future economics rather than current profit. Two figures pull against each other: the milestone line tripled year over year while the royalty line was ~$0.3M for the quarter, so the near-term earnings power comes from stage payments rather than product sales. Cash of ~$52M with essentially no debt and first-half operating burn of ~$2.2M means the balance sheet is not the pressing question at these levels; the timing of partner programs is.

How do you decide if OABI is a buy?

Rather than asking whether OABI is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold OABI indirectly through an index or sector ETF before adding more.

What would change your mind on OABI

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Clinical graduation across ~34 partner programs stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the OABI stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about OABI against your real portfolio and see your actual exposure before deciding.

Investing in OmniAb with AI

Connect the broker you already use and ask Walnut's AI how OABI fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

See how it fits your portfolio

FAQ

Is OABI a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Clinical graduation across ~34 partner programs, with revenue (ttm) at ~$38M. The bear case rests on revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. Analysts covering it are spread from $3.00 to $11.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell OABI?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $3.00, -11.2% from the $3.38 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for OABI?

Clinical graduation across ~34 partner programs. The economics compound only as partner molecules move through phases, and 2026 delivered several jumps at once, including two programs advancing from Phase 1 to Phase 3 and four new clinical entrants through mid-year. The most optimistic analyst target on OABI is $11.00, +225.4% from the $3.38 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for OABI?

What does OmniAb do?

OmniAb, spun out of Ligand Pharmaceuticals in 2022, licenses antibody discovery technology to drugmakers and earns milestones and royalties rather than selling medicines.

What would have to change for OABI to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Clinical graduation across ~34 partner programs) stalling in the reported numbers rather than in the narrative, the risk above (revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does OmniAb actually sell?

Access to antibody discovery technology, not medicines. Partners license platforms such as OmniRat, OmniMouse, OmniChicken and OmniTaur, or purchase xPloration screening instruments and ion channel services, then run their own programs. OmniAb collects access fees, service revenue, milestones as programs advance, and royalties on any product that reaches the market.

Is OmniAb profitable?

Not yet. Q2 2026 net loss was ~$5.9M, improved from ~$15.9M a year earlier, and the trailing twelve-month loss is around ~$44M. A large slice of that is non-cash amortisation of intangibles acquired before and during the Ligand spin-off, which is why first-half operating cash use was only ~$2.2M against a much larger reported loss.

Why did the revenue triple in Q2 2026?

License and milestone revenue accounted for ~$9.5M of the ~$13.4M quarter, driven by partner programs hitting contracted stages. Johnson & Johnson's ramantamig and Merck KGaA's precemtabart tocenteban both moved from Phase 1 to Phase 3. Management has said milestone revenue varies materially quarter to quarter and that 2026 activity is front-loaded, so the quarter is not a run rate.

Walnut is informational, not investment advice, and gives no verdict on OABI. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.